1. Thoracoscopic and endoscopic cooperative surgery (TECS): a novel less invasive technique for resection of gastric tube cancer after esophagectomy.
   Tsujii Y, Yamasaki M, Hayashi Y, Tanaka K, Makino T, Doki Y, Takehara T.
   Endoscopy. 2019 Jan;51(1):E5-E6.
2. Valsalva maneuver to visualize the closed hypopharyngeal space during transoral endoscopy using a novel dedicated mouthpiece.
   Kato M, Hayashi Y, Takehara T.
   Dig Endosc. 2019 Jan;31(1):e24-e25.
3. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
   Takehara T, Sakamoto N, Nishiguchi S, Ikeda F, Tatsumi T, Ueno Y, Yatsuhashi H, Takikawa Y, Kanda T, Sakamoto M, Tamori A, Mita E, Chayama K, Zhang G, De-Oertel S, Dvory-Sobol H, Matsuda T, Stamm LM, Brainard DM, Tanaka Y, Kurosaki M.
   J Gastroenterol. 2019 Jan;54(1):87-95.
4. A prospective multicenter observational study evaluating the risk of periendoscopic events in patients using anticoagulants: the Osaka GIANT Study.
   Inoue T, Iijima H, Yamada T, Okuyama Y, Takahashi K, Nishida T, Ishihara R, Akasaka T, Kobayashi I, Kuroshima T, Yasunaga Y, Yamamoto K, Nakahara M, Doi Y, Nakajima S, Mukai A, Masuda E, Yoshii S, Hayashi Y, Minamiguchi H, Sakata Y, Yamamoto K, Tsujii M, Takehara T.
   Endosc Int Open. 2019 Feb;7(2):E104-E114.
5. DNase II activated by the mitochondrial apoptotic pathway regulates RIP1-dependent non-apoptotic hepatocyte death via the TLR9/IFN-β signaling pathway.
   Saito Y, Hikita H, Nozaki Y, Kai Y, Makino Y, Nakabori T, Tanaka S, Yamada R, Shigekawa M, Kodama T, Sakamori R, Tatsumi T, Takehara T.
   Cell Death Differ. 2019 Mar;26(3):470-486.
6. The heart's exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer: a retrospective cohort study.
   Hayashi Y, Iijima H, Isohashi F, Tsujii Y, Fujinaga T, Nagai K, Yoshii S, Sakatani A, Hiyama S, Shinzaki S, Makino T, Yamasaki M, Ogawa K, Doki Y, Takehara T.
   BMC Cancer. 2019 Mar 4;19(1):195.
7. CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Cancer and a Molecular Target for Therapy.
   Kimura H, Yamamoto H, Harada T, Fumoto K, Osugi Y, Sada R, Maehara N, Hikita H, Mori S, Eguchi H, Ikawa M, Takehara T, Kikuchi A.
   Clin Cancer Res. 2019 Mar 15;25(6):1936-1947.
8. Core fucose is essential glycosylation for CD14-dependent Toll-like receptor 4 and Toll-like receptor 2 signalling in macrophages.
   Nakayama K, Wakamatsu K, Fujii H, Shinzaki S, Takamatsu S, Kitazume S, Kamada Y, Takehara T, Taniguchi N, Miyoshi E.
   J Biochem. 2019 Mar 1;165(3):227-237.
9. Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients.
   Nitta S, Asahina Y, Kato T, Tsuchiya J, Inoue-Shinomiya E, Sato A, Tsunoda T, Miyoshi M, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Hikita H, Takehara T, Watanabe M.
   Sci Rep. 2019 Apr 5;9(1):5722.
10. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update.
    Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, Torimura T, Moriyama M, Sakaida I, Okada H, Chiba T, Chuma M, Nakao K, Isomoto H, Sasaki Y, Kaneko S, Masaki T, Chayama K, Koike K.
    J Gastroenterol. 2019 Apr;54(4):367-376.
11. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A, Hikita H, Kai Y, Tahata Y, Saito Y, Nakabori T, Yamada R, Kodama T, Sakamori R, Murayama A, Nitta S, Asahina Y, Suemizu H, Tatsumi T, Kato T, Takehara T.
    J Gastroenterol. 2019 May;54(5):449-458.
12. Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response.
    Yamada R, Hiramatsu N, Oze T, Urabe A, Tahata Y, Morishita N, Kodama T, Hikita H, Sakamori R, Yakushijin T, Yamada A, Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K14, Tamura S, Inoue A, Imai Y, Tatsumi T, Hamasaki T, Hayashi N, Takehara T.
    Hepatol Res. 2019 May;49(5):570-578.
13. Left atrial appendage thrombus detected by transesophageal examination with linear endoscopic ultrasound.
    Ikezawa K, Shigekawa M, Sengoku K, Yoshioka T, Sakamori R, Sakata Y, Takehara T.
    Clin Case Rep. 2019 May 28;7(7):1327-1330.
14. Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation.
    Sasaki Y, Sakamori R, Yamada R, Shigekawa M, Tahata Y, Makino Y, Nakabori T, Kodama T, Hikita H, Tatsumi T, Takehara T.
    Hepatol Res. 2019 May 22.
15. Esophageal carcinosarcoma that disappeared pathologically by palliative radiotherapy alone.
    Kimura K, Hayashi Y, Otani K, Tsujii Y, Iijima H, Isohashi F, Ogawa K, Takehara T.
    Clin J Gastroenterol. 2019 Jun;12(3):247-253.
16. Endoscopic submucosal dissection for remnant rectal neoplasm after ileal pouch-anal anastomosis for ulcerative colitis.
    Yoshii S, Shinzaki S, Hayashi Y, Tsujii Y, Ashida M, Iijima H, Takehara T.
    Endoscopy. 2019 Jul 30.
17. Exosomal microRNAs derived from colon cancer cells promote tumor progression by suppressing fibroblast TP53 expression.
    Yoshii S, Hayashi Y, Iijima H, Inoue T, Kimura K, Sakatani A, Nagai K, Fujinaga T, Hiyama S, Kodama T, Shinzaki S, Tsujii Y, Watabe K, Takehara T.
    Cancer Sci. 2019 Aug;110(8):2396-2407.
18. Predictive factors of anemia during sofosbuvir and ribavirin therapy for genotype 2 chronic hepatitis C patients.
    Urabe A, Sakamori R, Tahata Y, Yamada R, Imai Y, Hagiwara H, Tamura S, Fukui H, Yamada Y, Kaneko A, Hijioka T, Kodama T, Hikita H, Tatsumi T, Takehara T.
    Hepatol Res. 2019 Aug;49(8):853-859.
19. Double-Scope Endoscopic Submucosal Dissection for a Laterally Spreading Cecal Tumor.
    Kimura K, Tsujii Y, Saiki H, Yoshii S, Hayashi Y, Takehara T.
    ACG Case Reports Journal. 2019 August; 6(8): p e00168.
20. GREB1 induced by Wnt signaling promotes development of hepatoblastoma by suppressing TGFβ signaling.
    Matsumoto S, Yamamichi T, Shinzawa K, Kasahara Y, Nojima S, Kodama T, Obika S, Takehara T, Morii E, Okuyama H, Kikuchi A.
    Nat Commun. 2019 Aug 28;10(1):3882.
21. Colorectal endoscopic submucosal dissection using "mucosal bridges" for local recurrence after endoscopic resection.
    Yoshii S, Hayashi Y, Tsujii Y, Iijima H, Takehara T.
    Endoscopy. 2019 Sep;51(9):E241-E242.
22. Soluble UL16-binding protein 2 is associated with a poor prognosis in pancreatic cancer patients.
    Kegasawa T, Tatsumi T, Yoshioka T, Suda T, Ikezawa K, Nakabori T, Yamada R, Kodama T, Shigekawa M, Hikita H, Sakamori R, Takehara T.
    Biochem Biophys Res Commun. 2019 Sep 10;517(1):84-88.
23. Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.
    Kodama K, Kawaguchi T, Hyogo H, Nakajima T, Ono M, Seike M, Takahashi H, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y, Fujii H, Seko Y, Takehara T, Itoh Y, Nakajima A, Masaki N, Torimura T, Saibara T, Karino Y, Chayama K, Tokushige K.
    J Gastroenterol Hepatol. 2019 Sep;34(9):1626-1632.
24. CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma.
    Suemura S, Kodama T, Myojin Y, Yamada R, Shigekawa M, Hikita H, Sakamori R, Tatsumi T, Takehara T.
    Cancers (Basel). 2019 Sep 13;11(9).
25. Efficacy of chemotherapy for older patients with gastric cancer: a multicenter retrospective cohort study.
    Hayashi Y, Nishida T, Tsutsui S, Ohta T, Yamaguchi S, Horimoto M, Masuda E, Narahara H, Sugimoto A, Tsujii Y, Suzuki K, Hagiwara H, Iijima H, Takehara T.
    Int J Clin Oncol. 2019 Nov;24(11):1377-1384.
26. Usefulness of intestinal real-time virtual sonography in patients with inflammatory bowel disease.
    Kawai S, Iijima H, Shinzaki S, Hiyama S, Yamaguchi T, Araki M, Iwatani S, Shiraishi E, Mukai A, Inoue T, Tsujii Y, Hayashi Y, Tsujii M, Takehara T.
    J Gastroenterol Hepatol. (In press)
27. Additional effect of magnifying narrow‐band imaging on estimating the invasion depth of superficial esophageal cancer.
    Kato M, Hayashi Y, Uema R, Kimura K, Inoue T, Sakatani A, Yoshii S, Tsujii Y, Shinzaki S, Iijima H, Takehara T
    JSH Open. (in press)
28. Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma.
    Maesaka K, Sakamori R, Yamada R, Tahata Y, Urabe A, Shigekawa M, Kodama T, Hikita H, Tatsumi T, Takehara T.
    Hepatol Res. (in press)

総説

1. Remaining challenges for the noninvasive diagnosis of esophageal varices in liver cirrhosis.
   Takehara T, Sakamori R. (in press)
   Esophagus. 2019 Oct 16.
2. NS5A-P32 deletion in hepatitis C genotype 1b infection is the most refractory treatment-mediated amino acid change exhibiting resistance to all NS5A inhibitors.
   Hikita H, Takehara T.
   Semin Liver Dis. (in press)

患者の皆様へ

学生・研修医のみなさまへ

阪大消化器内科のご紹介